v3.26.1
Scope of Consolidation and Non-Consolidated Entities - Additional Information (Detail)
1 Months Ended 12 Months Ended
Jun. 01, 2023
May 31, 2023
shares
May 17, 2023
shares
Dec. 29, 2022
Product
Nov. 23, 2022
Jun. 30, 2023
Dec. 31, 2025
Sep. 30, 2024
shares
May 28, 2024
shares
May 12, 2024
shares
Mar. 05, 2024
shares
Nov. 06, 2023
shares
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Ownership interest in subsidiary 100.00%         100.00%            
Ownership interest in associate         2.40%              
Number of shares issued               238 135,980 2,120 204,334 16,000,000
Cibus Global [Member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Ownership interest in subsidiary 2.90%                      
Cibus Global [Member] | Class A Common Stock [Member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Number of shares issued   16,527,484                    
Cellectis, Inc. [Member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Ownership interest in subsidiary             100.00%          
Cellectis, Inc. [Member] | Cellectis Biologics, Inc. [Member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Ownership interest in subsidiary             100.00%          
Calyxt [member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Ownership interest in subsidiary   48.00%                    
Primera Therapeutics, Inc. [Member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Name of associate       Primera Therapeutics, Inc.                
Maximum number of exclusive license for product candidates | Product       5                
Number of common stock received     234,570                  
Ownership interest in associate     19.00%       17.00%          
Voting rights held in associate     19.00%       17.00%          
Calyxt ATM Program [Member]                        
Disclosure of Information about Consolidated and Non-consolidated Structured Entities [Line Items]                        
Non-controlling shareholders interest   52.00%